Lv3
330 积分 2024-04-03 加入
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
1个月前
已完结
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up
1个月前
已关闭
Bayesian pairwise meta‐analysis of time‐to‐event outcomes in the presence of non‐proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models
1个月前
已关闭
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
1个月前
已完结
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
1个月前
已完结
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
1个月前
已完结
Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code
3个月前
已完结
Cooking Up a Transparent Model Following a DICE Recipe
3个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
4个月前
已完结
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
5个月前
已完结
皖公网安备34019202002308
